These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1706768)

  • 1. MHC-restricted cytotoxicity against HIV.
    Autran B; Plata F; Debre P
    J Acquir Immune Defic Syndr (1988); 1991; 4(4):361-7. PubMed ID: 1706768
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytotoxic T-cell recognition of HIV proteins and peptides.
    Nixon DF; McMichael AJ
    AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV/AIDS. HLA leaves its footprints on HIV.
    McMichael A; Klenerman P
    Science; 2002 May; 296(5572):1410-1. PubMed ID: 12029119
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cytotoxic T cells against HIV].
    Autran B; Debré P
    Presse Med; 1990 Sep; 19(31):1435-7. PubMed ID: 1700412
    [No Abstract]   [Full Text] [Related]  

  • 5. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication.
    Yang OO; Walker BD
    Adv Immunol; 1997; 66():273-311. PubMed ID: 9328644
    [No Abstract]   [Full Text] [Related]  

  • 6. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
    Achour A; Picard O; Zagury D; Sarin PS; Gallo RC; Naylor PH; Goldstein AL
    Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7045-9. PubMed ID: 1698289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
    Kundu SK; Merigan TC
    AIDS; 1992 Jul; 6(7):643-9. PubMed ID: 1354446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV immunization. Fresh pathways to follow.
    Bolognesi DP
    Nature; 1990 Apr; 344(6269):818-9. PubMed ID: 1691822
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
    Dorrell L; Willcox BE; Jones EY; Gillespie G; Njai H; Sabally S; Jaye A; DeGleria K; Rostron T; Lepin E; McMichael A; Whittle H; Rowland-Jones S
    Eur J Immunol; 2001 Jun; 31(6):1747-56. PubMed ID: 11385619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does the HIV escape cytotoxic T cell immunity?
    Phillips RE; McMichael AJ
    Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV T cell vaccines, the importance of clades.
    McMichael A; Mwau M; Hanke T
    Vaccine; 2002 May; 20(15):1918-21. PubMed ID: 11983245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function.
    Kostense S; Ogg GS; Manting EH; Gillespie G; Joling J; Vandenberghe K; Veenhof EZ; van Baarle D; Jurriaans S; Klein MR; Miedema F
    Eur J Immunol; 2001 Mar; 31(3):677-86. PubMed ID: 11241270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Repertoire of epitopes of human immunodeficiency virus proteins and the search for vaccines and diagnostic kits].
    Kharchenko EP; Klimenko AP
    Dokl Akad Nauk SSSR; 1992; 322(1):189-92. PubMed ID: 1380907
    [No Abstract]   [Full Text] [Related]  

  • 14. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
    McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
    J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human class I MHC-restricted cytotoxic T-lymphocytes specific for human immunodeficiency virus envelope antigens.
    Shepp DH; Daguillard F; Mann D; Quinnan GV
    AIDS; 1988 Apr; 2(2):113-7. PubMed ID: 2454643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence.
    McChesney M; Tanneau F; Regnault A; Sansonetti P; Montagnier L; Kieny MP; Rivière Y
    Eur J Immunol; 1990 Jan; 20(1):215-20. PubMed ID: 2106442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 18. CTL cross reactivity between HIV strains.
    Jolly D; Chada S; Townsend K; DeJesus C; Chang S; Weinhold K; Anderson CG; Lynn A; Bodner M; Barber J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1369-71. PubMed ID: 1466957
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance of HIV-infected cells to cytotoxic T lymphocytes.
    Collins KL
    Microbes Infect; 2004 Apr; 6(5):494-500. PubMed ID: 15109965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.
    Gruters RA; van Baalen CA; Osterhaus AD
    Vaccine; 2002 May; 20(15):2011-5. PubMed ID: 11983265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.